Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsThe rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.
A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.
New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.
Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.
This rheumatology month in review emphasizes new data from the ACR Convergence.
New data support firsekibart's efficacy over colchicine for preventing acute gout flares.
A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.
1.
Study identifies new approach to protect the brain during radiation therapy
2.
Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis
3.
Remote monitoring can improve recovery from cancer surgery
4.
A study has developed molecular markers that predict meningioma recurrence.
5.
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma
1.
Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies
2.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
3.
Breaking Barriers in Cancer Treatment: The Role of Innovative Oncology Drugs
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge